Mitochondrial-Derived Peptides: Overview

Mitochondria are most famous as cellular power plants, but mounting evidence suggests they are also signaling organs. Encoded within mitochondrial DNA are genes for small peptides — collectively called mitochondrial-derived peptides (MDPs) — that leave the mitochondrion and carry messages to the nucleus and systemic circulation. This emerging field is upending our understanding of metabolic regulation and aging. This overview covers the major MDPs and why they matter for research.

The discovery: "microproteins" in mitochondrial DNA

Mitochondrial DNA (mtDNA) was long thought to encode only 13 proteins (the core enzymes of the electron transport chain) plus ribosomal and transfer RNAs. However, around 2015, researchers discovered that "junk" regions of mtDNA — previously thought non-coding — actually encode small peptides (60–100 amino acids) that are synthesized in mitochondria and exported.

These peptides are now recognized as genuine signaling molecules, not junk. They are termed mitochondrial-derived peptides (MDPs) or sometimes "microproteins."

The three known MDPs: MOTS-c, humanina, and SHLPs

1. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It is the most extensively studied MDP. Circulating MOTS-c levels decline with age, and low levels correlate with metabolic dysfunction and age-related diseases. Key functions include:

• Metabolic regulation: Enhances insulin sensitivity, improves glucose clearance, and increases mitochondrial ATP production.
• AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism.
• Lifespan extension (in mice): Transgenic mice overexpressing MOTS-c live longer and have improved metabolic health.

2. Humanina

Humanina is a 24-amino-acid peptide encoded within the 16S rRNA gene of mitochondrial DNA. It was the first MDP discovered and was named for its neuroprotective effects (hence "human" + "retina"). Key roles include:

• Neuroprotection: Protects neurons from amyloid-beta and oxidative stress in models of Alzheimer's disease.
• Anti-apoptosis: Antagonizes pro-death signaling in stressed cells.
• Metabolic benefits: Some studies show humanina improves glucose metabolism, though this is less consistent than MOTS-c data.

Like MOTS-c, humanina levels decline with age and metabolic disease.

3. SHLPs (Small Humanina-like peptides)

SHLPs are a family of humanina-related peptides (SHLP1–SHLP6) also encoded in mitochondrial DNA. They share structural similarity to humanina and show some overlap in function (neuroprotection, stress resistance), but their individual roles are less well-characterized. Research is ongoing.

How MDPs work: retrograde signaling

The key concept is retrograde signaling — a signal from the mitochondrion (organelle) back to the nucleus (control center) and to the systemic circulation (whole-body communication):

1. Synthesis in mitochondria: MDPs are translated on mitochondrial ribosomes using their own tRNA and synthesis machinery.
2. Export from mitochondria: The mechanisms for export are not fully clear, but MDPs somehow cross the inner mitochondrial membrane and enter the cytoplasm.
3. Receptor binding: MDPs bind to cell-surface or intracellular receptors (the specific receptors for most MDPs remain under investigation).
4. Downstream signaling: MOTS-c activates AMPK; humanina inhibits pro-apoptotic factors. The precise pathways are still being mapped.
5. Systemic distribution: MDPs are found in circulating blood, suggesting they act on distant tissues, not just locally.

Why MDPs decline with age and disease

Several factors contribute to reduced MDP levels in aging:

• Mitochondrial dysfunction: As mitochondria accumulate damage (oxidative stress, DNA mutations) with age, their capacity to produce MDPs declines.
• Reduced mitochondrial biogenesis: Aging involves loss of mitochondrial renewal (mitophagy, mitochondrial biogenesis), so new MDP-producing mitochondria are not generated.
• Metabolic disease: Obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD) all associate with lower MOTS-c and humanina levels.

This creates a vicious cycle: low MDPs → metabolic dysfunction → further mitochondrial damage → even lower MDPs.

Research and therapeutic potential

MDPs are generating excitement because:

• Early human trials: MOTS-c Phase II trials are underway for prediabetes and metabolic disease.
• Broad relevance: MDPs affect metabolism, neuroprotection, and aging — broad-impact domains affecting millions.
• Biomarker potential: Circulating MDP levels may serve as biomarkers for mitochondrial health and aging trajectory.
• Drug target: Therapies that boost endogenous MDP production (e.g., by promoting mitochondrial biogenesis via SIRT1, PGC-1α) are in preclinical development.

Current evidence gaps

Despite excitement, several questions remain unanswered:

• MDP receptors: The cell-surface receptors for MOTS-c and humanina are not conclusively identified.
• Tissue specificity: Which tissues are most responsive to which MDPs? Do MDPs act systemically or preferentially in certain organs?
• Human translationability: Rodent data are encouraging, but human Phase III efficacy and safety trials are not yet complete.
• Pharmacokinetics: How stable are synthetic MDPs in circulation? What is the optimal dosing schedule?

Related reading on mitochondrial and metabolic research

• MOTS-c August 2026: What New Metabolic Research Shows
• MOTS-c Research Guide: Mechanism & Preclinical Findings
• Cardiolipin & Mitochondrial Membranes
• Shop mitochondrial and metabolic peptides

Shop research peptides →

Sources & further reading

• Diabetes & Metabolism Journal. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. e-dmj.org
• SourcePeptides. MOTS-C Peptide Research Guide: Mechanisms and Mitochondrial Biology (2026). sourcepeptides.co
• PeptIQ. MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Tests. peptiq.io